According to the latest report by IMARC Group, titled “Pen Needles Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” The global pen needles market reached a value of US$2.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$6.5 Billion by 2027, exhibiting at a CAGR of 15.01% during 2022-2027.
Pen needles are injector pens that are used for delivering medication into the body of a patient. They consist of hollow needles embedded in a plastic body that is connected to the injection pen. Pen needles are used by health professionals and patients who are suffering from diabetes. Nowadays, they are available in a variety of needle lengths and diameters. Pen needles are manufactured with fine and thin point tips made by electro-polishing the needles to offer ease of use and penetration. They also have plastic caps for safety and lubrication for easy glide and less friction.
The pen needles market is primarily driven by the rising prevalence of chronic and lifestyle diseases like diabetes, osteoporosis, cardiovascular diseases, and multiple sclerosis. In addition, pen needles are cost-effective, portable, and do not require refrigeration for daily or weekly drug administration through pen injectors. Besides this, pen injectors are gaining popularity as the new standard for injectable drug delivery systems due to their simplicity, reliability, and the ability to be administered directly by the patient without the aid of a physician. Furthermore, factors such as the rising geriatric population, inflating healthcare expenditure, and favorable government policies are some of the other factors that are expected to significantly impact the market in the coming years.
Request Free Sample Report: https://www.imarcgroup.com/pen-needles-market/requestsample
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare) and Ultimed Inc.
The report has segmented the market on the basis on region, type, needle length, therapy, mode of purchase, end user.
Breakup by Type:
- Standard Pen Needles
- Safety Pen Needles
Breakup by Needle Length:
Breakup by Therapy:
- Growth Hormones
Breakup by Mode of Purchase:
Breakup by End User:
- Hospitals and Clinics
- Home Healthcare
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/pen-needles-market
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800